HighVista Strategies’s Krystal Biotech KRYS Stock Holding History

HighVista Strategies’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Buy	3,260 +1,436	+79%	+$429K	0.28%	103
2026 Q1	$471K	Buy	+1,824	New	+$485K	0.13%	150
2025 Q1	–	Sell	-4,217	Closed	-$661K	–	158
2024 Q4	$661K	Buy	+4,217	New	+$748K	0.25%	119
2024 Q2	–	Sell	-3,923	Closed	-$698K	–	145
2024 Q1	$698K	Buy	+3,923	New	+$545K	0.25%	106
2023 Q4	–	Sell	-4,392	Closed	-$509K	–	136
2023 Q3	$509K	Buy	4,392 +1,862	+74%	+$227K	0.24%	106
2023 Q2	$297K	Sell	2,530 -8,528	-77%	-$871K	0.14%	133
2023 Q1	$885K	Hold	11,058	–	–	0.72%	42
2022 Q4	$876K	Buy	11,058 +4,023	+57%	+$299K	0.52%	57
2022 Q3	$490K	Sell	7,035 -5,190	-42%	-$375K	0.28%	82
2022 Q2	$803K	Buy	+12,225	New	+$760K	0.48%	48

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HighVista Strategies's KRYS Position: Q2 2026 in Review

HighVista Strategies increased its Krystal Biotech (KRYS) stake by 79% in Q2 2026, buying an estimated $429K and bringing the position to 3,260 shares worth $1.21M. The position accounts for 0.28% of the portfolio, ranked #103.

HighVista Strategies first reported a position in KRYS in Q2 2022 and has held it in 10 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

HighVista Strategies held 3,260 shares of Krystal Biotech worth $1.21M as of Q2 2026.
HighVista Strategies bought 1,436 Krystal Biotech shares in Q2 2026, an estimated $429K.
Krystal Biotech made up 0.28% of HighVista Strategies's portfolio in Q2 2026, its #103 holding.
HighVista Strategies first reported a position in Krystal Biotech in Q2 2022 and has held it in 10 quarters since.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.